EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Market data and deal flow

Sources

Dose Diligence research deskSection 11 · Page 11 of 11Last updated 17 Nov 2026

Sources below were located during this research. Live commercial pages were checked November 17, 2026; dated releases and studies retain their stated observation periods. Supplier statements are identified as such. Media, job-board, video and podcast searches were used for discovery, not as proof of capacity or market size.

  1. ASHP — US prescription drug spending and 2025 GLP-1 share; April 30, 2026
  2. AJHP — National trends in prescription drug expenditures and projections for 2026; published April 30, 2026
  3. IQVIA — U.S. Medicine Use Trends 2026; April 28, 2026
  4. Eli Lilly — Q3 2026 financial results; October 29, 2026
  5. Eli Lilly — Q3 2026 earnings slides; October 29, 2026
  6. Novo Nordisk — Nine-month 2026 financial report; November 4, 2026
  7. CDC — GLP-1 use among US adults, July–August 2025 survey; November 12, 2026
  8. NovoCare — Wegovy savings offers; live page
  9. Lilly — Zepbound HCP coverage and savings; live page
  10. Lilly — Foundayo full offer terms; live page
  11. Novo Nordisk — Wegovy subscription program; March 31, 2026
  12. CMS — Medicare GLP-1 Bridge program; live page
  13. CMS — Medicare GLP-1 Bridge expectations and FAQs
  14. Novo Nordisk — List-price reduction effective January 1, 2027; February 24, 2026
  15. LifeMD — Q3 2026 results; November 12, 2026
  16. Eli Lilly — Pennsylvania manufacturing groundbreaking; November 12, 2026
  17. Blackstone — Pfizer obesity-development funding agreement; November 11, 2026
  18. Hims & Hers — Lilly access agreement; November 6, 2026
  19. Hims & Hers — Q3 2026 Form 10-Q, including Eucalyptus acquisition
  20. Photon Health — Series A announcement; April 30, 2026
  21. Photon Health — Company-issued financing release; April 30, 2026
  22. Novo Nordisk — Hims & Hers agreement; March 9, 2026
  23. LifeMD Pharmacy — B2B branded GLP-1 program; live page
  24. FDA — Compounding policy clarification; April 1, 2026 update
  25. FDA — Proposed exclusion from the 503B bulks list; April 30, 2026
  26. FDA — GLP-1 safety-labeling communication; November 9, 2026

Sources cited on this page

  1. news.ashp.org · Source 1 ↗https://news.ashp.org/news/ashp-news/2026/04/30/us-prescription-drug-spending-poised-to-cross-1-trillion-with-weight-loss-drugs
  2. academic.oup.com · Source 2 ↗https://academic.oup.com/ajhp/article/83/14/728/8662887
  3. iqvia.com · Source 3 ↗https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026
  4. lilly.gcs-web.com · Source 4 ↗https://lilly.gcs-web.com/node/55191/pdf
  5. investor.lilly.com · Source 5 ↗https://investor.lilly.com/static-files/4580c401-611c-406b-8964-88cb8d887bd4
  6. sec.gov · Source 6 ↗https://www.sec.gov/Archives/edgar/data/353278/000162828026069805/caq32026.htm
  7. cdc.gov · Source 7 ↗https://www.cdc.gov/mmwr/volumes/75/wr/mm7544a1.htm
  8. novocare.com · Source 8 ↗https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
  9. zepbound.lilly.com · Source 9 ↗https://zepbound.lilly.com/hcp/coverage-savings
  10. lilly.com · Source 10 ↗https://www.lilly.com/lillydirect/foundayo/foundayo-full-terms-conditions
  11. novonordisk-us.com · Source 11 ↗https://www.novonordisk-us.com/media/press-releases/wegovy-subscription-program-telehealth-savings.html
  12. cms.gov · Source 12 ↗https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
  13. cms.gov · Source 13 ↗https://www.cms.gov/files/document/medicare-glp-1-bridge-expectations-faqs.pdf
  14. novonordisk-us.com · Source 14 ↗https://www.novonordisk-us.com/media/press-releases/novo-nordisk-lowers-wegovy-ozempic-list-price.html
  15. sec.gov · Source 15 ↗https://www.sec.gov/Archives/edgar/data/948320/000149315226051397/ex99-1.htm
  16. lilly.gcs-web.com · Source 16 ↗https://lilly.gcs-web.com/node/55301/pdf
  17. blackstone.com · Source 17 ↗https://www.blackstone.com/news/press/pfizer-and-blackstone-life-sciences-announce-strategic-funding-agreement-for-obesity-program/
  18. investors.hims.com · Source 18 ↗https://investors.hims.com/news/news-details/2026/Lilly-and-Hims--Hers-expand-access-to-FDA-approved-Lilly-medicines/default.aspx
  19. sec.gov · Source 19 ↗https://www.sec.gov/Archives/edgar/data/1773751/000177375126000246/hims-20260930.htm
  20. photonhealth.com · Source 20 ↗https://photonhealth.com/blog/series-a-growth-in-darkness
  21. prnewswire.com · Source 21 ↗https://www.prnewswire.com/news-releases/photon-raises-16m-series-a-to-give-patients-control-over-their-prescriptions-and-bring-transparency-to-pharmacy-302754817.html
  22. novonordisk.com · Source 22 ↗https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916512
  23. lifemdpharmacy.com · Source 23 ↗https://lifemdpharmacy.com/glp-1
  24. fda.gov · Source 24 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  25. fda.gov · Source 25 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  26. fda.gov · Source 26 ↗https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
Section sources →